Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) was $3.01 for the day, up 3.79% from the previous closing price of $2.90. In other words, the price has increased by $3.79 from its previous closing price. On the day, 0.78 million shares were traded. XERS stock price reached its highest trading level at $3.01 during the session, while it also had its lowest trading level at $2.86.
Ratios:
Our analysis of XERS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.79.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 12 ’24 when Schmid John P. bought 4,515 shares for $2.25 per share. The transaction valued at 10,147 led to the insider holds 25,200 shares of the business.
Schmid John P. bought 4,285 shares of XERS for $10,134 on Aug 09 ’24. The Director now owns 20,685 shares after completing the transaction at $2.37 per share. On May 10 ’24, another insider, Schmid John P., who serves as the Director of the company, bought 5,400 shares for $1.91 each. As a result, the insider paid 10,314 and bolstered with 16,400 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 448733792 and an Enterprise Value of 633899264. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.40. Its current Enterprise Value per Revenue stands at 3.383 whereas that against EBITDA is -19.172.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $3.64, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is -0.40%, while the 200-Day Moving Average is calculated to be 20.43%.
Shares Statistics:
XERS traded an average of 1.62M shares per day over the past three months and 2644280 shares per day over the past ten days. A total of 149.08M shares are outstanding, with a floating share count of 141.37M. Insiders hold about 5.17% of the company’s shares, while institutions hold 43.56% stake in the company. Shares short for XERS as of 1730332800 were 11373240 with a Short Ratio of 7.04, compared to 1727654400 on 11094553. Therefore, it implies a Short% of Shares Outstanding of 11373240 and a Short% of Float of 7.8200005.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.22 and -$0.3 for the fiscal current year, implying an average EPS of -$0.26. EPS for the following year is -$0.2, with 3.0 analysts recommending between -$0.12 and -$0.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $58M to a low estimate of $51.52M. As of the current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $44.39MFor the next quarter, 6 analysts are estimating revenue of $53.67M. There is a high estimate of $57M for the next quarter, whereas the lowest estimate is $51.2M.
A total of 6 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $201M, while the lowest revenue estimate was $191.4M, resulting in an average revenue estimate of $198.43M. In the same quarter a year ago, actual revenue was $163.91MBased on 6 analysts’ estimates, the company’s revenue will be $234.23M in the next fiscal year. The high estimate is $260M and the low estimate is $218.1M.
